You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Cost recovery implementation statement: Blood, blood components and biologicals (human cell and tissue therapies), From 1 July 2015
Version 1.0, July 2015
Key forward events
An independent Review of Medicines and Medical Devices Regulation (Expert Review) was announced on 24 October 2014. The aim of the Expert Review was to examine the TGA's regulatory framework and processes with a view to identifying:
- Areas of unnecessary, duplicative, or ineffective regulation that could be removed or streamlined without undermining the safety or quality of therapeutic goods available in Australia; and
- Opportunities to enhance the regulatory framework so that Australia continues to be well positioned to respond effectively to global trends in the development, manufacture, marketing and regulation of therapeutic goods.
During 2015-16 implementation of Government agreed recommendations from the Expert Review will begin. The Government has committed to boost productivity and reduce regulation through its deregulation agenda. The deregulation agenda is guided by the principle that regulation should only be imposed where absolutely necessary, and should not be the default position for dealing with public policy issues.
|Key forward events schedule||Next scheduled update|
|Forward (financial) estimates||30 June 2016|
|Update of actual (financial) results||Reported in the Department of Health's Annual Report|
|Stakeholder engagement round||Second quarter 2015-16|
|Scheduled portfolio charging review||2017-18|